BidaskClub downgraded shares of Corindus Vascular Robotics Inc (NYSEMKT:CVRS) from a hold rating to a sell rating in a report published on Friday.

Other research analysts also recently issued reports about the stock. B. Riley restated a buy rating and set a $3.00 target price on shares of Corindus Vascular Robotics in a research report on Monday, May 15th. ValuEngine upgraded shares of Corindus Vascular Robotics from a sell rating to a hold rating in a research report on Thursday, June 22nd. Finally, Zacks Investment Research downgraded shares of Corindus Vascular Robotics from a hold rating to a sell rating in a research report on Tuesday, May 16th.

Shares of Corindus Vascular Robotics (NYSEMKT CVRS) opened at 1.74 on Friday. The company’s market capitalization is $325.52 million. Corindus Vascular Robotics has a 52-week low of $0.40 and a 52-week high of $2.25. The firm’s 50 day moving average is $1.76 and its 200-day moving average is $1.21.

Corindus Vascular Robotics (NYSEMKT:CVRS) last issued its quarterly earnings data on Tuesday, May 9th. The medical equipment provider reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.02. Corindus Vascular Robotics had a negative return on equity of 181.63% and a negative net margin of 1,272.20%. The company had revenue of $0.78 million for the quarter, compared to the consensus estimate of $1.59 million. Equities research analysts anticipate that Corindus Vascular Robotics will post ($0.22) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/07/corindus-vascular-robotics-inc-cvrs-downgraded-by-bidaskclub-to-sell.html.

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its stake in shares of Corindus Vascular Robotics by 40.7% in the second quarter. Bank of New York Mellon Corp now owns 229,380 shares of the medical equipment provider’s stock worth $426,000 after buying an additional 66,368 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Corindus Vascular Robotics by 67.6% in the second quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock worth $150,000 after buying an additional 32,608 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Corindus Vascular Robotics by 240.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 285,900 shares of the medical equipment provider’s stock worth $375,000 after buying an additional 201,900 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Corindus Vascular Robotics by 73.3% in the first quarter. Geode Capital Management LLC now owns 673,488 shares of the medical equipment provider’s stock worth $882,000 after buying an additional 284,855 shares in the last quarter.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.